Immunomedics Announces Six Presentations on Epratuzumab in

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Immunomedics Announces Six Presentations on Epratuzumab in Lupus at Leading Rheumatology Meeting

MORRIS PLAINS, N.J., Nov. 14, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc. , (Nasdaq: IMMU ) today announced that partner UCB, S.A., responsible for the development of epratuzumab in non-oncology indications, is sponsoring 6 presentations on investigational studies of epratuzumab in systemic lupus erythematosus (SLE) at the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting, November 14 – 19, 2014 in Boston, MA.

Epratuzumab is an investigational medicine in Phase 3 development for SLE. It is not approved for the treatment of SLE by any regulatory authority worldwide.

Following is a guide to the investigational studies of epratuzumab being presented:

1. [2834]: Correlation of Laboratory and Clinical Parameters with British Isles Lupus Assessment Group Response in an Open-Label Extension Study of Epratuzumab in Systemic Lupus Erythematosus
Furie, R. A. et al.

  • Date/Time: Tuesday November 18; 2:45 pm – 3:00 pm
  • Session Info: Oral Presentation, Boston Convention and Exhibition Center: 205 B

2. [2873]: Epratuzumab Induces Broad Inhibition of B Cell Receptor Proximal Signaling but Has Opposing Effects on Distal Signaling in B cell Subsets: A Profile of Effects on Functional Immune Signaling by Single Cell Network Profiling
Maloney, A. et al.

  • Date/Time: Tuesday November 18; 5:30 pm – 5:45 pm
  • Session Info: Oral Presentation, Boston Convention and Exhibition Center: 109 A

3. [1942]: Regulation of the Responses of Human B Cell Subsets to Innate Immune Signals by Epratuzumab, a Humanized Monoclonal Antibody Targeting CD22
Giltiay, N. V. et al.

  • Date/Time: Tuesday November 18; 8:30 am – 4:00 pm
  • Session Info: Poster Session, Exhibit Hall B

4. [1943]: In Vivo Effects of Epratuzumab, a Monoclonal Antibody Targeting Human CD22, on B Cell Function in Human CD22 Knock-In (Huki) Mice
Brandl, C. et al.

  • Date/Time: Tuesday November 18; 8:30 am – 4:00 pm
  • Session Info: Poster Session, Exhibit Hall B

5. [1944]: Targeting CD22 with Epratuzumab Impacts Cytokine Production by B Cells
Fleischer, V. et al.

  • Date/Time: Tuesday November 18; 8:30 am – 4:00 pm
  • Session Info: Poster Session, Exhibit Hall B

6. [1945]: Pharmacodynamic Effects of the CD22-Targeted Monoclonal Antibody Epratuzumab on B cells in Patients with Systemic Lupus Erythematosus
Shock, A. et al.

  • Date/Time: Tuesday November 18; 8:30 am – 4:00 pm
  • Session Info: Poster Session, Exhibit Hall B

About Immunomedics

Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Immunomedics' advanced proprietary technologies allow the Company to create humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. Using these technologies, Immunomedics has built a pipeline of nine clinical-stage product candidates. Immunomedics has an ongoing collaboration with UCB, S.A. (UCB), to whom the Company licensed epratuzumab for the treatment of all non-cancer indications worldwide. UCB expects Phase 3 data in systemic lupus erythematosus in the first half of 2015. Immunomedics is exploring epratuzumab in oncology in collaboration with independent cancer study groups. Immunomedics' most advanced candidate to which it retains worldwide rights for all indications is 90 Y-clivatuzumab tetraxetan. The Company initiated a Phase 3 registration trial in January 2014 in patients with advanced pancreatic cancer and expects topline data in mid-2016. Immunomedics' portfolio of wholly owned product candidates also includes antibody-drug conjugates (ADCs) that are designed to deliver a specific payload of a chemotherapeutic directly to the tumor while reducing overall toxic effects that are usually found with conventional administration of these chemotherapeutic agents. Immunomedics' most advanced ADCs are IMMU-132 and IMMU-130, which are in Phase 2 trials for a number of solid tumors and metastatic colorectal cancer, respectively. Immunomedics also has a number of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various stages of clinical and pre-clinical development. These include bispecific antibodies targeting cancers and infectious diseases as T-cell redirecting immunotherapies, as well as bispecific antibodies for next-generation cancer and autoimmune disease therapies, created using its patented DOCK-AND-LOCK ® protein conjugation technology. The Company believes that its portfolio of intellectual property, which includes approximately 259 active patents in the United States and more than 400 foreign patents, protects its product candidates and technologies. Immunomedics' strength in intellectual property has resulted in a top-8 ranking in the Biotechnology industry by the Patent Board for the 2014 fiscal year. For additional information on the Company, please visit its website at www.immunomedics.com . The information on its website does not, however, form a part of this press release.

This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials (including the funding therefor, outcomes, timing or associated costs), out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, potential collaborations, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, availability of required financing and other sources of funds on acceptable terms, if at all, new product development (including clinical trials outcome and regulatory requirements/actions), our dependence on UCB for the further development of epratuzumab for non-cancer indications, risks associated with the outcome of pending litigation and competitive risks to marketed products, as well as the risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

For More Information: Dr. Chau Cheng Senior Director, Investor Relations & Grant Management (973) 605-8200, extension 123

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Telit Cinterion Tests Its Defense Connectivity Pitch

Updated Category News Views 107

Defense connectivity is a messy business, and Telit Cinterion is leaning straight into the mess at NATO Edge 2026 in Izmir, Turkey. From November 17 through 19, the company is using Booth L86 to show how several wireless links can live inside one mission-focused setup. That may sound like standard trade-show wallpaper, but the underlying problem is very real: military and...

Continue Reading
Hyster-Yale's $125 Million Convertible Debt Shuffle

Updated Category News Views 86

Forklifts do not make headlines often, but debt terms sure can. Hyster-Yale has proposed a $125 million private offering of convertible senior notes due November 15, 2031, with buyers able to take another $18.75 million if the initial purchasers exercise their option. For NYSE:HY holders, this is not a victory lap or a distress flare by itself. It is a refinancing...

Continue Reading
Innoviz's 1-for-20 Split Is a Listing Lifeline Test

Updated Category News Views 45

A twenty-share pile of INVZ is about to become one share, and nobody should confuse that paperwork with a turnaround. Innoviz plans to enact a 1-for-20 reverse split at 11:59 p.m. Eastern on Friday, December 4, with split-adjusted trading expected when Nasdaq opens on December 7. This is a blunt instrument aimed at one immediate problem: getting the quoted share price...

Continue Reading
Sectra's RSNA AI Pitch Centers on Workflow, Not Hype

Updated Category News Views 121

Radiology has heard enough grand AI promises to fill a hospital basement, which makes Sectra's RSNA 2026 message refreshingly grounded. The Swedish imaging IT and cybersecurity company is putting its weight behind the unglamorous part of adoption: fitting AI into the daily diagnostic machinery without handing clinicians another awkward system to babysit. That is where...

Continue Reading
Sysco's Northern California Labor Deal Gets Bigger

Updated Category News Views 20

One hundred forty-four drivers may not rattle a giant food distributor by themselves, but labor agreements have a habit of growing legs. Sysco's Northern California and Nevada regional contract has added members from Teamsters Locals 386 and 431, bringing its coverage above 1,100 workers. For investors watching Sysco, this is less about one afternoon's headline and more...

Continue Reading
Oracle Takes AI to Construction's Messy Project Middle

Updated Category News Views 164

A stalled drywall inspection can wreck a schedule faster than any glossy AI pitch can repair it. That is the grimy, practical corner Oracle is aiming at with its latest Oracle Primavera Cloud upgrades: the daily hunt for answers, the repeated logging of familiar risks, and the finger-pointing that starts when a milestone is suddenly in danger. This is not a chatbot being...

Continue Reading
Cadence Marks $2.7 Million for St. Jude Family Care

Updated Category News Views 112

Small Wheels, Serious Purpose Tiny tricycles, flour-dusted bake-sale tables, and family pledges have pushed Cadence Education’s St. Jude partnership to $2.7 million since 2018. That number is not a flashy balance-sheet item, nor should anybody try to dress it up as one. It is the accumulated result of school communities showing up year after year, and in a sector built...

Continue Reading
Elijah Craig Uses AI Toasts to Sell a Warmer Pour

Updated Category News Views 38

A Speech Prompt With a Bourbon Label Few things expose holiday nerves faster than a raised glass and a room waiting for somebody to say something memorable. Elijah Craig has decided that awkward little moment is marketing territory, rolling out its Digital Perfect Pour, Perfect Toast Generator for mobile and desktop users ahead of the holiday season. The tool asks for a...

Continue Reading
TORM Rejects Hafnia's No-Premium Merger Pitch Again

Updated Category News Views 112

A 19.8% shareholder heading for the exit can rattle a shipping stock before breakfast, and TORM has answered the noise with a flat refusal to pretend Hafnia's merger approach was good enough. The message from Hellerup on November 18 is unusually blunt: Hafnia made several conditional, all-share proposals, TORM saw no effective premium for control, and the board rejected...

Continue Reading
Gozney Brings in Armin Boehm for a Global Growth Push

Updated Category News Views 95

A pizza oven company has just made a very grown-up management move. Gozney appointed Armin Boehm as Global President, effective from October 31, putting an experienced consumer-brand operator beside founder, designer and CEO Tom Gozney at a moment when the business says it is becoming a global omnichannel operation. This is not the sort of announcement that comes with...

Continue Reading

Top 5 Most Recently Viewed Articles

Shell PLC's Strategic Share Repurchase Program Explained

Updated Category News Views 198

Understanding Shell PLC's Share Repurchase Strategy Shell plc has recently made headlines with its ongoing share buyback program. On a notable date, the company announced a significant purchase of its own shares intended for cancellation. This action is a part of its broader strategy to enhance shareholder value and optimize its capital structure. Details of the Share...

Continue Reading
Teck Resources Faces Maintenance Challenges at Chile Operations

Updated Category News Views 255

Maintenance Updates from Teck Resources Limited Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) has recently reported important updates regarding maintenance challenges at its operations in Chile. A mechanical issue has emerged at the Carmen de Andacollo (CdA) site, necessitating a temporary shutdown of the SAG mill. According to the latest information,...

Continue Reading
Neinor Homes Achieves FY24 Targets and New Shareholder Returns

Updated Category News Views 151

Neinor Homes Achieves Fiscal Targets for 2024 In a recent update, Neinor Homes reports successful fulfillment of its Adjusted Net Income target of €65 million for fiscal year 2024. The company, known for its prominence in residential property development, is now poised for continued growth. With the expected announcement of its fiscal results set for the latter part of...

Continue Reading
STG Logistics Staff Earn Supply Chain Accolades

Updated Category News Views 41

There's a fresh breeze running through the corridors of STG Logistics. Why? Because two of their own have snagged some serious recognition with the 2026 Women in Supply Chain Awards. This isn't just another blip on the corporate radar—it's a salute to the powerhouse of leadership and innovation nestled within the company's ranks. Geoff Anderman, the CEO himself, was...

Continue Reading
WISeKey International Holding Ltd Unveils AGM Agenda for Stakeholders

Updated Category News Views 284

WISeKey International Holding Ltd Unveils AGM Agenda for Stakeholders WISeKey International Holding Ltd, recognized for its significant contributions in the fields of cybersecurity and IoT, has announced the essential items for consideration by its shareholders at the upcoming Annual General Meeting (AGM). This important gathering, set to foster engagement between...

Continue Reading